Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2017-12-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
关于放弃子公司增资扩股优先认缴权暨关联交易的公告之补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a corporate transaction involving the waiver of a subsidiary's capital increase subscription rights and related party transactions. It includes background, purpose, necessity, and rationality of the transaction, detailed financial forecasts, independent directors' opinions, asset transfer details, and future disclosure arrangements. The content focuses on a specific capital and financing update related to the company's business operations and investment activities, rather than a full financial report, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive transaction details and analysis. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-12-07 Chinese
2017年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2017 second extraordinary shareholders' meeting of Chengdu Berry Genomics Co., Ltd. It details the meeting date, attendance, voting results on various proposals, related party transactions, and legal opinions confirming the legality and validity of the meeting and resolutions. The content focuses on the official voting results and decisions made at the shareholders' meeting, including the approval of capital increase agreements and authorization to the chairman. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official announcement of the voting results from a shareholders' meeting. The document length is about 4008 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-12-03 Chinese
2017年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of a specific shareholders' meeting (the 2017 second extraordinary general meeting) of a company. It details the legal compliance of the meeting process and the validity of the resolutions passed. The document does not contain financial statements or financial performance data, nor is it an announcement of a report publication. It is focused on the shareholder meeting and the voting results. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (3195 characters), and it is a detailed legal opinion on the voting results, not just a brief announcement, so it is not RPA or RNS. Hence, the classification is DVA with high confidence.
2017-12-03 Chinese
关于召开2017年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed announcement about the convening of the 2017 second extraordinary general meeting of shareholders for Chengdu Berry Genomics Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures (both onsite and online), registration methods, and proxy authorization forms. The content focuses on notifying shareholders about the meeting and how to participate and vote on specific proposals, including related-party transactions and capital increase authorizations. There are no financial statements, audit opinions, or management discussions of financial results. The document is not a report itself but an official notice and instructions for a shareholders' meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2017-11-28 Chinese
关于召开2017年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2017 second extraordinary general meeting of shareholders for the company. It includes information about the meeting time, location, agenda items, voting procedures (both in-person and online), registration methods, and proxy authorization forms. The content focuses on the announcement and procedural details for a shareholder meeting rather than the meeting materials, voting results, or financial reports. There is no indication that this is a report of voting results or a proxy solicitation document, but rather a formal notice to shareholders about the meeting itself. Therefore, the document fits best into the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings, including notices of meetings.
2017-11-16 Chinese
中信建投证券股份有限公司关于公司放弃子公司增资扩股优先认缴权暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure regarding a company's decision to waive its subsidiary's preemptive rights in a capital increase and related party transactions. It includes extensive information about the transaction, involved parties, agreements, board resolutions, and regulatory compliance references. The content focuses on a specific corporate transaction involving capital increase, asset transfer, and related agreements, with detailed terms and conditions. It is not a general financial report, earnings release, or management discussion. It is not a simple announcement or a proxy solicitation but a comprehensive disclosure of a significant related party transaction and capital increase waiver. This fits best under the category of Capital/Financing Update (CAP), as it deals with capital structure changes and financing-related transactions.
2017-11-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.